Status:

UNKNOWN

Neo-RT: A Study Investigating Whether Changing the Sequence of Treatments (Starting Radiotherapy Followed by Hormone Therapy Before Surgery) is Feasible

Lead Sponsor:

CCTU- Cancer Theme

Collaborating Sponsors:

Breast Cancer Now

CRUK Cambridge Institute

Conditions:

Breast Cancer

Eligibility:

FEMALE

18+ years

Brief Summary

Four in 10 women diagnosed with breast cancer undergo mastectomy with or without breast reconstruction and less than half are satisfied with how they look unclothed. Breast conservation (removing the ...

Eligibility Criteria

Inclusion

  • Written informed consent to participate
  • Female
  • Aged 18 years and older
  • ECOG performance status 0-2
  • Histology confirmed invasive breast cancer
  • ER positive (Allred score 6-8)
  • HER2 negative
  • Palpable size ≥20mm
  • Grade I-II (or grade III if considered not suitable for neo-adjuvant chemotherapy)
  • Considered that radiotherapy will make breast conserving surgery easier
  • No evidence of non-breast malignancy if treated with curative intent unless the patient has been disease free ≥5 years
  • Unifocal or multifocal disease, i.e. tumour in the same quadrant and breast conserving surgery still feasible

Exclusion

  • Contraindications to breast radiotherapy or neo-adjuvant endocrine therapy
  • Bilateral breast cancer
  • Metastatic cancer
  • Multicentric disease
  • Concomitant medical/psychiatric problems preventing completion of study treatment or follow-up
  • Pregnancy
  • Breast feeding

Key Trial Info

Start Date :

March 26 2018

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2022

Estimated Enrollment :

43 Patients enrolled

Trial Details

Trial ID

NCT03818100

Start Date

March 26 2018

End Date

December 31 2022

Last Update

July 27 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cambridge University Hospitals NHS Foundation Trust

Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ